MA52967A - Composés antagonistes du pcsk9 - Google Patents

Composés antagonistes du pcsk9

Info

Publication number
MA52967A
MA52967A MA052967A MA52967A MA52967A MA 52967 A MA52967 A MA 52967A MA 052967 A MA052967 A MA 052967A MA 52967 A MA52967 A MA 52967A MA 52967 A MA52967 A MA 52967A
Authority
MA
Morocco
Prior art keywords
antagonist compounds
pcsk9 antagonist
pcsk9
compounds
antagonist
Prior art date
Application number
MA052967A
Other languages
English (en)
Inventor
Elisabetta Bianchi
Sobhana Babu Boga
Danila Branca
Fa-Xiang Ding
Sookhee Nicole Ha
Hubert B Josien
Angela Dawn Kerekes
Jian Liu
Anilkumar G Nair
Ling Tong
Thomas Joseph Tucker
Abbas M Walji
Harold B Wood
Chengwei Wu
Yusheng Xiong
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA52967A publication Critical patent/MA52967A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6454Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21061Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MA052967A 2018-06-21 2019-06-20 Composés antagonistes du pcsk9 MA52967A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
MA52967A true MA52967A (fr) 2021-04-28

Family

ID=67263083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052967A MA52967A (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9

Country Status (25)

Country Link
US (2) US11427616B2 (fr)
EP (1) EP3810626A1 (fr)
JP (2) JP7112531B2 (fr)
KR (1) KR20210024035A (fr)
CN (1) CN112313243A (fr)
AR (1) AR115597A1 (fr)
AU (2) AU2019290163C1 (fr)
BR (1) BR112020025274A8 (fr)
CA (1) CA3102629A1 (fr)
CL (2) CL2020003257A1 (fr)
CO (1) CO2021000456A2 (fr)
CR (1) CR20210031A (fr)
DO (1) DOP2020000250A (fr)
EA (1) EA202190086A1 (fr)
EC (1) ECSP21003643A (fr)
GE (1) GEP20237506B (fr)
IL (1) IL279363A (fr)
JO (1) JOP20190150A1 (fr)
MA (1) MA52967A (fr)
MX (1) MX2020013726A (fr)
NI (1) NI202000101A (fr)
PE (1) PE20211584A1 (fr)
PH (1) PH12020552187A1 (fr)
SG (1) SG11202012451WA (fr)
WO (1) WO2019246349A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
ES2901704T3 (es) 2013-03-15 2022-03-23 Protagonist Therapeutics Inc Análogos de hepcidina y usos de los mismos
EP3143037B1 (fr) 2014-05-16 2021-06-23 Protagonist Therapeutics, Inc. Antagonistes peptidiques de l'intégrine alpha4beta7 contenant des thioéthers
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CA3089868A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimetiques d'hepcidine conjugues
EP3810178A4 (fr) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
JOP20190150A1 (ar) * 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
WO2019246405A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
EP3810177A4 (fr) 2018-06-21 2022-05-11 RA Pharmaceuticals, Inc. Peptides cycliques pour l'inhibition de la pcsk9
WO2019246386A1 (fr) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Polypeptides cycliques pour l'inhibition de la pcsk9
WO2021041770A1 (fr) * 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
EP4076492A4 (fr) * 2019-12-20 2024-01-17 Merck Sharp & Dohme Llc Composés antagonistes du pcsk
EP4090670A1 (fr) 2020-01-15 2022-11-23 Janssen Biotech, Inc. Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
AU2022330007A1 (en) 2021-08-19 2024-02-15 Merck Sharp & Dohme Llc Compounds for treating conditions related to pcsk9 activity
TW202404574A (zh) 2022-06-15 2024-02-01 美商默沙東有限責任公司 用於捕捉介白素-1 β之環狀肽

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
ATE253073T1 (de) 1997-03-07 2003-11-15 Metabasis Therapeutics Inc Neue benzimidazol inhibitoren der fructose-1,6- bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
SK286080B6 (sk) 1998-09-09 2008-03-05 Metabasis Therapeutics, Inc. Heterocyklické aromatické zlúčeniny obsahujúce fosfonátovú skupinu, ich použitie a farmaceutická kompozícia obsahujúca uvedené zlúčeniny
EP1305285B1 (fr) 2000-07-25 2007-05-16 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
JP4181408B2 (ja) 2001-01-30 2008-11-12 メルク エンド カムパニー インコーポレーテッド 肥満、糖尿病及び脂質異常を治療するためのアシルスルファミド類
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004020408A1 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles a activite antidiabetique
US7393960B2 (en) 2002-08-29 2008-07-01 Merck & Co., Inc. Indoles having anti-diabetic activity
AU2004207444B2 (en) 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
EP2170883A1 (fr) 2007-06-28 2010-04-07 Merck Frosst Canada Ltd. Pyrimidines fusionnées substituées en tant qu'antagonistes de l'activité de gpr105
KR101404781B1 (ko) 2007-06-28 2014-06-12 가부시키가이샤 한도오따이 에네루기 켄큐쇼 반도체 장치의 제조 방법
WO2009042053A2 (fr) 2007-09-21 2009-04-02 Merck & Co., Inc. Agonistes du récepteur de la neuromédine u et leurs utilisations
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
US20140113874A1 (en) 2010-09-23 2014-04-24 The Trustees Of The University Of Pennsylvania Modified Compstatin With Improved Stability And Binding Properties
KR101510975B1 (ko) 2010-12-28 2015-04-10 카딜라 핼쓰캐어 리미티드 이상지질혈증의 치료에 적절한 헤테로시클릭 화합물
CA2837658A1 (fr) 2011-06-20 2012-12-27 Genentech, Inc. Polypeptides liant pcsk9 et leurs procedes d'utilisation
UA119028C2 (uk) 2011-10-27 2019-04-25 Массачусеттс Інстітьют Оф Текнолоджі Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб
EP2814501A4 (fr) 2012-03-13 2016-03-02 Tensive Controls Inc Analogues de mélanocortine présentant une activité et un transport améliorés
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
RU2015142437A (ru) 2013-03-14 2017-04-27 Дайити Санкио Ко., Лтд Новые связывающие белки для pcsk9
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションShifa Biomedical Corporation 抗プロタンパク質転換酵素サブチリシン/ケキシン9型(抗pcsk9)化合物および心血管疾患の治療および/または予防におけるその使用方法
US10557129B2 (en) 2015-01-30 2020-02-11 Pronasci Inc. Peptides derived from human PCSK9 catalytic domain and uses thereof for promoting LDL-R activity
EP3442991A4 (fr) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. Peptides de liaison à ras et méthodes d'utilisation
WO2017220701A1 (fr) 2016-06-24 2017-12-28 F. Hoffmann-La Roche Ag Compositions et méthodes de traitement de maladie cardiovasculaire
WO2018053517A1 (fr) 2016-09-19 2018-03-22 The Texas A&M University System Inhibiteurs de l'interaction protéine-protéine ldlr-pcsk9 et leurs procédés d'utilisation
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
EP3810178A4 (fr) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
US11306125B2 (en) 2018-06-21 2022-04-19 Merck Sharp & Dohme Corp. PCSK9 antagonists bicyclo-compounds
WO2019246386A1 (fr) 2018-06-21 2019-12-26 Ra Pharmaceuticals Inc. Polypeptides cycliques pour l'inhibition de la pcsk9
WO2019246405A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
EP3810177A4 (fr) 2018-06-21 2022-05-11 RA Pharmaceuticals, Inc. Peptides cycliques pour l'inhibition de la pcsk9
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
WO2021041770A1 (fr) 2019-08-30 2021-03-04 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9

Also Published As

Publication number Publication date
AU2019290163C1 (en) 2022-11-03
AU2019290163A1 (en) 2021-01-07
JOP20190150A1 (ar) 2019-12-21
NI202000101A (es) 2021-05-28
IL279363A (en) 2021-01-31
DOP2020000250A (es) 2021-02-28
US20190389909A1 (en) 2019-12-26
ECSP21003643A (es) 2021-02-26
MX2020013726A (es) 2021-03-02
EA202190086A1 (ru) 2021-05-18
CO2021000456A2 (es) 2021-01-29
US20230159592A1 (en) 2023-05-25
PE20211584A1 (es) 2021-08-18
BR112020025274A2 (pt) 2021-03-09
CL2020003257A1 (es) 2021-07-23
AU2019290163B2 (en) 2022-08-04
WO2019246349A1 (fr) 2019-12-26
CL2022000027A1 (es) 2022-08-19
TW202019950A (zh) 2020-06-01
CN112313243A (zh) 2021-02-02
KR20210024035A (ko) 2021-03-04
CR20210031A (es) 2021-02-11
JP2021522311A (ja) 2021-08-30
PH12020552187A1 (en) 2021-07-26
AU2022259744A1 (en) 2022-12-01
BR112020025274A8 (pt) 2023-02-14
AR115597A1 (es) 2021-02-03
US11427616B2 (en) 2022-08-30
GEP20237506B (en) 2023-05-25
SG11202012451WA (en) 2021-01-28
JP7112531B2 (ja) 2022-08-03
WO2019246349A8 (fr) 2021-02-04
JP2022141879A (ja) 2022-09-29
CA3102629A1 (fr) 2019-12-26
EP3810626A1 (fr) 2021-04-28

Similar Documents

Publication Publication Date Title
MA52967A (fr) Composés antagonistes du pcsk9
MA52948A (fr) Composés
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
MA51669A (fr) Composés
MA53003A (fr) Composés
DK3737677T3 (da) Tetrahydroisoquinolinforbindelser
MA52946A (fr) Composés
DK3738452T3 (da) Fordamper
IT201900004161A1 (it) Composti fluoroarilossibenzoeterodiazolici disostituiti
MA54534A (fr) Antagonistes
UA40242S (uk) Набір свердел
ES1243687Y (es) Salmorejo
IT201900020430A1 (it) Espositore
UA41181S (uk) Кальян
DE202019004111U8 (de) Weichenstellvorichtung
TH190914S (th) ขันโตก
TH190911S (th) ขันโตก
TH190910S (th) ขันโตก
DK3786413T3 (da) Rullejalousi
ES1235736Y (es) Alcoholimetro
ES1234309Y (es) Bolardo
ES1231789Y (es) Inodoro
UA40179S (uk) Кальян
ES1232841Y (es) Barbacoa plancha
ES1231191Y (es) Vela-lazo